268 related articles for article (PubMed ID: 20713596)
1. Viral entry and escape from antibody-mediated neutralization influence hepatitis C virus reinfection in liver transplantation.
Fafi-Kremer S; Fofana I; Soulier E; Carolla P; Meuleman P; Leroux-Roels G; Patel AH; Cosset FL; Pessaux P; Doffoël M; Wolf P; Stoll-Keller F; Baumert TF
J Exp Med; 2010 Aug; 207(9):2019-31. PubMed ID: 20713596
[TBL] [Abstract][Full Text] [Related]
2. A novel neutralizing human monoclonal antibody broadly abrogates hepatitis C virus infection in vitro and in vivo.
Desombere I; Mesalam AA; Urbanowicz RA; Van Houtte F; Verhoye L; Keck ZY; Farhoudi A; Vercauteren K; Weening KE; Baumert TF; Patel AH; Foung SKH; Ball J; Leroux-Roels G; Meuleman P
Antiviral Res; 2017 Dec; 148():53-64. PubMed ID: 29074219
[TBL] [Abstract][Full Text] [Related]
3. In vivo combination of human anti-envelope glycoprotein E2 and -Claudin-1 monoclonal antibodies for prevention of hepatitis C virus infection.
Mailly L; Wrensch F; Heydmann L; Fauvelle C; Brignon N; Zeisel MB; Pessaux P; Keck ZY; Schuster C; Fuerst TR; Foung SKH; Baumert TF
Antiviral Res; 2019 Feb; 162():136-141. PubMed ID: 30599173
[TBL] [Abstract][Full Text] [Related]
4. Mutations in hepatitis C virus E2 located outside the CD81 binding sites lead to escape from broadly neutralizing antibodies but compromise virus infectivity.
Keck ZY; Li SH; Xia J; von Hahn T; Balfe P; McKeating JA; Witteveldt J; Patel AH; Alter H; Rice CM; Foung SK
J Virol; 2009 Jun; 83(12):6149-60. PubMed ID: 19321602
[TBL] [Abstract][Full Text] [Related]
5. A novel monoclonal anti-CD81 antibody produced by genetic immunization efficiently inhibits Hepatitis C virus cell-cell transmission.
Fofana I; Xiao F; Thumann C; Turek M; Zona L; Tawar RG; Grunert F; Thompson J; Zeisel MB; Baumert TF
PLoS One; 2013; 8(5):e64221. PubMed ID: 23704981
[TBL] [Abstract][Full Text] [Related]
6. Neutralizing host responses in hepatitis C virus infection target viral entry at postbinding steps and membrane fusion.
Haberstroh A; Schnober EK; Zeisel MB; Carolla P; Barth H; Blum HE; Cosset FL; Koutsoudakis G; Bartenschlager R; Union A; Depla E; Owsianka A; Patel AH; Schuster C; Stoll-Keller F; Doffoël M; Dreux M; Baumert TF
Gastroenterology; 2008 Nov; 135(5):1719-1728.e1. PubMed ID: 18718838
[TBL] [Abstract][Full Text] [Related]
7. Broad neutralization of hepatitis C virus-resistant variants by Civacir hepatitis C immunoglobulin.
Tawar RG; Heydmann L; Bach C; Schüttrumpf J; Chavan S; King BJ; McClure CP; Ball JK; Pessaux P; Habersetzer F; Bartenschlager R; Zeisel MB; Baumert TF
Hepatology; 2016 Nov; 64(5):1495-1506. PubMed ID: 27531416
[TBL] [Abstract][Full Text] [Related]
8. Preclinical evaluation of two neutralizing human monoclonal antibodies against hepatitis C virus (HCV): a potential treatment to prevent HCV reinfection in liver transplant patients.
Eren R; Landstein D; Terkieltaub D; Nussbaum O; Zauberman A; Ben-Porath J; Gopher J; Buchnick R; Kovjazin R; Rosenthal-Galili Z; Aviel S; Ilan E; Shoshany Y; Neville L; Waisman T; Ben-Moshe O; Kischitsky A; Foung SK; Keck ZY; Pappo O; Eid A; Jurim O; Zamir G; Galun E; Dagan S
J Virol; 2006 Mar; 80(6):2654-64. PubMed ID: 16501075
[TBL] [Abstract][Full Text] [Related]
9. Mutations that alter use of hepatitis C virus cell entry factors mediate escape from neutralizing antibodies.
Fofana I; Fafi-Kremer S; Carolla P; Fauvelle C; Zahid MN; Turek M; Heydmann L; Cury K; Hayer J; Combet C; Cosset FL; Pietschmann T; Hiet MS; Bartenschlager R; Habersetzer F; Doffoël M; Keck ZY; Foung SKH; Zeisel MB; Stoll-Keller F; Baumert TF
Gastroenterology; 2012 Jul; 143(1):223-233.e9. PubMed ID: 22503792
[TBL] [Abstract][Full Text] [Related]
10. Expanding the Host Range of Hepatitis C Virus through Viral Adaptation.
von Schaewen M; Dorner M; Hueging K; Foquet L; Gerges S; Hrebikova G; Heller B; Bitzegeio J; Doerrbecker J; Horwitz JA; Gerold G; Suerbaum S; Rice CM; Meuleman P; Pietschmann T; Ploss A
mBio; 2016 Nov; 7(6):. PubMed ID: 27834208
[TBL] [Abstract][Full Text] [Related]
11. A Diverse Panel of Hepatitis C Virus Glycoproteins for Use in Vaccine Research Reveals Extremes of Monoclonal Antibody Neutralization Resistance.
Urbanowicz RA; McClure CP; Brown RJ; Tsoleridis T; Persson MA; Krey T; Irving WL; Ball JK; Tarr AW
J Virol; 2015 Dec; 90(7):3288-301. PubMed ID: 26699643
[TBL] [Abstract][Full Text] [Related]
12. Hepatitis C virus envelope glycoprotein signatures are associated with treatment failure and modulation of viral entry and neutralization.
Schvoerer E; Moenne-Loccoz R; Murray JM; Velay A; Turek M; Fofana I; Fafi-Kremer S; Erba AC; Habersetzer F; Doffoël M; Gut JP; Donlin MJ; Tavis JE; Zeisel MB; Stoll-Keller F; Baumert TF
J Infect Dis; 2013 Apr; 207(8):1306-15. PubMed ID: 23335805
[TBL] [Abstract][Full Text] [Related]
13. Human monoclonal antibody HCV1 effectively prevents and treats HCV infection in chimpanzees.
Morin TJ; Broering TJ; Leav BA; Blair BM; Rowley KJ; Boucher EN; Wang Y; Cheslock PS; Knauber M; Olsen DB; Ludmerer SW; Szabo G; Finberg RW; Purcell RH; Lanford RE; Ambrosino DM; Molrine DC; Babcock GJ
PLoS Pathog; 2012; 8(8):e1002895. PubMed ID: 22952447
[TBL] [Abstract][Full Text] [Related]
14. A novel small molecule inhibitor of hepatitis C virus entry.
Baldick CJ; Wichroski MJ; Pendri A; Walsh AW; Fang J; Mazzucco CE; Pokornowski KA; Rose RE; Eggers BJ; Hsu M; Zhai W; Zhai G; Gerritz SW; Poss MA; Meanwell NA; Cockett MI; Tenney DJ
PLoS Pathog; 2010 Sep; 6(9):e1001086. PubMed ID: 20838466
[TBL] [Abstract][Full Text] [Related]
15. Sequence and functional analysis of the envelope glycoproteins of hepatitis C virus variants selectively transmitted to a new host.
D'Arienzo V; Moreau A; D'Alteroche L; Gissot V; Blanchard E; Gaudy-Graffin C; Roch E; Dubois F; Giraudeau B; Plantier JC; Goudeau A; Roingeard P; Brand D
J Virol; 2013 Dec; 87(24):13609-18. PubMed ID: 24109215
[TBL] [Abstract][Full Text] [Related]
16. Neutralizing antibodies and pathogenesis of hepatitis C virus infection.
Fafi-Kremer S; Fauvelle C; Felmlee DJ; Zeisel MB; Lepiller Q; Fofana I; Heydmann L; Stoll-Keller F; Baumert TF
Viruses; 2012 Oct; 4(10):2016-30. PubMed ID: 23202451
[TBL] [Abstract][Full Text] [Related]
17. Additional glycosylation within a specific hypervariable region of subtype 3a of hepatitis C virus protects against virus neutralization.
Anjum S; Wahid A; Afzal MS; Albecka A; Alsaleh K; Ahmad T; Baumert TF; Wychowski C; Qadri I; Penin F; Dubuisson J
J Infect Dis; 2013 Dec; 208(11):1888-97. PubMed ID: 23908491
[TBL] [Abstract][Full Text] [Related]
18. Hepatitis C virus entry into hepatocytes: molecular mechanisms and targets for antiviral therapies.
Zeisel MB; Fofana I; Fafi-Kremer S; Baumert TF
J Hepatol; 2011 Mar; 54(3):566-76. PubMed ID: 21146244
[TBL] [Abstract][Full Text] [Related]
19. Expression, immunogenicity and diagnostic value of envelope proteins from an Egyptian hepatitis C virus isolate.
Shawky H; Maghraby AS; Solliman Mel-D; El-Mokadem MT; Sherif MM; Arafa A; Bahgat MM
Arch Virol; 2015 Apr; 160(4):945-58. PubMed ID: 25631616
[TBL] [Abstract][Full Text] [Related]
20. Neutralizing activities of caprine antibodies towards conserved regions of the HCV envelope glycoprotein E2.
El Abd YS; Tabll AA; El Din NG; Hosny Ael-D; Moustafa RI; El-Shenawy R; Atef K; El-Awady MK
Virol J; 2011 Aug; 8():391. PubMed ID: 21819575
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]